Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Effectiveness of Multi-strain Versus Single-strain Probiotics: Current Status and Recommendations for the Future

Ouwehand, Arthur C., PhD*; Invernici, Marcos M., PhD; Furlaneto, Flávia A.C., PhD; Messora, Michel R., PhD

Journal of Clinical Gastroenterology: November/December 2018 - Volume 52 - Issue - p S35–S40
doi: 10.1097/MCG.0000000000001052
PRESENTATION

Probiotics are investigated as single-strain and multistrain products. In the market, however, there is an increasing tendency to work with multistrain probiotics, in particular, products with a high number of different strains. There are some thoughts behind this: more strains imply more chances of success; it can mean a broader spectrum of efficacy, and there is often the hope that there are at least additive and, potentially, even synergistic effects. The present review did not find convincing evidence that these assumptions are valid. There is, however, also no strong evidence that the assumptions are incorrect and/or that there is antagonistic activity between strains in a combination. We suggest that, to answer these questions, structured research is conducted. Starting with a systematic review of meta-analyses that have compared single-strain and multistrain probiotic efficacy, dedicated human studies need to be performed, comparing single-strain and multistrain probiotics to each other and placebo. In vitro and animal studies can provide indications and may help understand mechanisms. For human, animal, and in vitro studies, it is recommended to work with the simple setup of 2 single strains, a 2-strain combination, and placebo. It is also important in such research to take into consideration the doses, as a combination product will have a higher total dose.

*Global Health & Nutrition Sciences, DuPont Nutrition & Health, Kantvik, Finland

Department of Oral and Maxillofacial Surgery and Periodontology, School of Dentistry of Ribeirao Preto, University of Sao Paulo—USP, Ribeirao Preto, Sao Paulo, Brazil

A.C.O. was funded by DuPont Nutrition & Health. M.M.I. was funded by University of Sao Paulo.

A.C.O. is an employee of DuPont Nutrition & Health. DuPont manufactures and markets probiotics. The remaining authors declare that they have nothing to disclose.

Address correspondence to: Arthur C. Ouwehand, PhD, Global Health & Nutrition Sciences, DuPont Nutrition & Health, Sokeritehtaantie 20, 02460 Kantvik, Finland (e-mail: arthur.ouwehand@dupont.com).

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.